Literature DB >> 10074145

Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines.

H Sakurai1, R A Williamson, J E Crowe, J A Beeler, P Poignard, R B Bastidas, R M Chanock, D R Burton.   

Abstract

A number of antibodies generated during human respiratory syncytial virus (RSV) infection have been cloned by the phage library approach. Antibodies reactive with an immunodominant epitope on the F glycoprotein of this virus have a high affinity for affinity-purified F antigen. These antibodies, however, have a much lower affinity for mature F glycoprotein on the surface of infected cells and are nonneutralizing. In contrast, a potent neutralizing antibody has a high affinity for mature F protein but a much lower affinity for purified F protein or F protein in viral lysates. The data indicate that at least two F protein immunogens are produced during natural RSV infection: immature F, found in viral lysates, and mature F, found on infected cells or virions. Binding studies with polyclonal human immunoglobulin G suggest that the antibody responses to the two immunogens are of similar magnitudes. Competitive binding studies suggest that overlap between the responses is relatively limited. A mature envelope with an antigenic configuration different from that of the immature envelope has an evolutionary advantage in that the infecting virus is less subject to neutralization by the humoral response to the immature envelope that inevitably arises following lysis of infected cells. Subunit vaccines may be at a disadvantage because they most often resemble immature envelope molecules and ignore this aspect of viral evasion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074145      PMCID: PMC104055     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology.

Authors:  U Jönsson; L Fägerstam; B Ivarsson; B Johnsson; R Karlsson; K Lundh; S Löfås; B Persson; H Roos; I Rönnberg
Journal:  Biotechniques       Date:  1991-11       Impact factor: 1.993

2.  A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees.

Authors:  J E Crowe; P T Bui; A R Davis; R M Chanock; B R Murphy
Journal:  Vaccine       Date:  1994-07       Impact factor: 3.641

3.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

4.  Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries.

Authors:  R A Williamson; R Burioni; P P Sanna; L J Partridge; C F Barbas; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

Review 5.  An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines.

Authors:  B R Murphy; S L Hall; A B Kulkarni; J E Crowe; P L Collins; M Connors; R A Karron; R M Chanock
Journal:  Virus Res       Date:  1994-04       Impact factor: 3.303

6.  Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice.

Authors:  J E Crowe; B R Murphy; R M Chanock; R A Williamson; C F Barbas; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

7.  Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein.

Authors:  J A López; D Andreu; C Carreño; P Whyte; G Taylor; J A Melero
Journal:  J Gen Virol       Date:  1993-12       Impact factor: 3.891

8.  Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries.

Authors:  C F Barbas; T A Collet; W Amberg; P Roben; J M Binley; D Hoekstra; D Cababa; T M Jones; R A Williamson; G R Pilkington
Journal:  J Mol Biol       Date:  1993-04-05       Impact factor: 5.469

9.  Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.

Authors:  C F Barbas; J E Crowe; D Cababa; T M Jones; S L Zebedee; B R Murphy; R M Chanock; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  Cloning and characterisation of TPO autoantibodies using combinatorial phage display libraries.

Authors:  J M Hexham; L J Partridge; J Furmaniak; V B Petersen; J C Colls; C Pegg; B Rees Smith; D R Burton
Journal:  Autoimmunity       Date:  1994       Impact factor: 2.815

View more
  23 in total

1.  Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Authors:  R W Sanders; L Schiffner; A Master; F Kajumo; Y Guo; T Dragic; J P Moore; J M Binley
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 2.  Genetic and structural determinants of virus neutralizing antibodies.

Authors:  J E Crowe; R O Suara; S Brock; N Kallewaard; F House; J H Weitkamp
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 3.  Current research on respiratory viral infections: Third International Symposium.

Authors:  A C Schmidt; R B Couch; G J Galasso; F G Hayden; J Mills; B R Murphy; R M Chanock
Journal:  Antiviral Res       Date:  2001-06       Impact factor: 5.970

4.  Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.

Authors:  Bo Liang; Sonja Surman; Emerito Amaro-Carambot; Barbora Kabatova; Natalie Mackow; Matthias Lingemann; Lijuan Yang; Jason S McLellan; Barney S Graham; Peter D Kwong; Anne Schaap-Nutt; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

Review 5.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

6.  Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats.

Authors:  Gabriella Cseke; David W Wright; Sharon J Tollefson; Joyce E Johnson; James E Crowe; John V Williams
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

7.  Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model.

Authors:  Reagan G Cox; John J Erickson; Andrew K Hastings; Jennifer C Becker; Monika Johnson; Ryan E Craven; Sharon J Tollefson; Kelli L Boyd; John V Williams
Journal:  J Virol       Date:  2014-03-26       Impact factor: 5.103

Review 8.  Protein engineering strategies for the development of viral vaccines and immunotherapeutics.

Authors:  Jayne F Koellhoffer; Chelsea D Higgins; Jonathan R Lai
Journal:  FEBS Lett       Date:  2013-10-21       Impact factor: 4.124

Review 9.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 10.  The host response and molecular pathogenesis associated with respiratory syncytial virus infection.

Authors:  Christine M Oshansky; Wenliang Zhang; Elizabeth Moore; Ralph A Tripp
Journal:  Future Microbiol       Date:  2009-04       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.